◑ We're currently building out coverage for Swiss-listed stocks (SIX Swiss Exchange). Other markets will follow.

BioVersys AG

CH0210362643 · BIOVSIX ·

CH · Healthcare · Stock

BioVersys AG is a Swiss clinical-stage biopharmaceutical company headquartered in Basel, focused on developing novel antibacterial therapies to combat antimicrobial resistance. The company applies its proprietary transcription factor-targeting platform to discover and advance small-molecule drug candidates against difficult-to-treat bacterial infections. Its pipeline includes programs targeting pathogens such as Mycobacterium tuberculosis and multi-drug-resistant Gram-negative bacteria.

Dividend Yield

—

TTM · SIX

Last Dividend

—

CHF

5Y Growth

—

CAGR

Frequency

None

Years Paid

—

consecutive

Not Cut

—

consecutive yrs

Grown

—

consecutive yrs

Listings

Exchange	Ticker	Currency	Yield TTM
SIX primary	BIOV	CHF	—

Total Return

Starting Amount 10'000 CHF

Price Gain −1'923 CHF

Dividends —

Total Return -19.23%

CAGR -19.24%

End Balance 8'077 CHF

Based on 10,000 invested at the start of the period. Price return uses split-adjusted closing prices. Dividends are not reinvested.

Annual Dividends

No dividend history available.

Dividend Yield History

Loading yield history…

ⓘ

Dividend History

Ex-Date ▼	Pay-Date ▼	Amount ▼	Type ▼
No dividend events found.